TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an announcement.
Clover Biopharmaceuticals Ltd. announced the grant of 5,964,000 options and 9,016,500 restricted stock units (RSUs) to eligible participants under its Post-IPO Share Option Plan and RSU Scheme. The options and RSUs are part of the company’s strategy to incentivize and retain talent by aligning employee and stakeholder interests with company performance. The options have a 10-year validity, with vesting conditions tied to group and individual performance targets, reflecting the company’s commitment to achieving long-term growth and operational success.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. The company is primarily focused on developing and commercializing vaccines and biologic therapeutic products.
YTD Price Performance: -7.08%
Average Trading Volume: 1,872,956
Technical Sentiment Signal: Buy
Current Market Cap: HK$287.9M
See more data about 2197 stock on TipRanks’ Stock Analysis page.